MARKETS / BALCAO / BETRF
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Betterlife Pharma Inc. BETRF

11 fiscal years on record · USD · FY2018 reported
SEC FILINGS ONLY
EPS · FY18
$-0.10
Dividend / sh · FY18
Payout · FY18
ROE · FY18
-529.6%
Net margin · FY18
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
Revenue, FY2018 · full 11-year series below
Revenue Net income
2.5e-105e-107.5e-101e-09-0.020082011201420172018
2.5e-105e-107.5e-101e-09-0.02009201220152018

Per share
USD -0.10
Diluted EPS, FY2018
EPS
0.40.81.2-0.1020082011201420172018
0.40.81.2-0.102009201220152018

The company pays no cash dividend.

Profitability
-529.6%
Return on equity, FY2018
ROE
0.250.50.751-529.6%20082011201420172018
0.250.50.751-529.6%2009201220152018
Operating margin
Net margin
Return on assets-201.7%

Each USD of equity lost 530 cents this year.

Returned to shareholders
returned in FY2018 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.10B
Shares outstanding, FY2018
0.040.1020082011201420172018
0.040.102009201220152018
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.6M
total assets, end of FY2018
Total assetsUSD 8.6M
EquityUSD 3.5M
CashUSD 74,800.00

Equity funds 41% of total assets.

History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
·
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
EBITDA $B
·
·
·
−0.0
−0.0
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.10
0.00
−0.08
−0.13
−0.10
−0.20
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−529.6
·
·
·
·
·
·
·
·
−708.9
−2199.4
Shares out B
0.10
0.08
0.08
0.07
0.07
0.01
0.04
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
22 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 1 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed